Showing 4181-4190 of 7767 results for "".
- Takeda Completes Acquisition of Nimbus’ TYK2 Subsidiaryhttps://practicaldermatology.com/news/takeda-completes-acquisition-of-nimbus-tyk2-subsidiary/2461552/Takeda has expanded its psoriasis treatment portfolio after completing its acquisition of Nimbus Lakshmi from Nimbus Therapeutics in a deal worth up to $6 billion. Under the agreement, which was announced on December 13, 2022, Takeda will acquire TAK-279, formerly known at Nim
- Meet TargetCool, CoolHealth's Solution to Post-Procedure Pain, Bruisinghttps://practicaldermatology.com/news/meet-targetcool-coolhealths-solution-to-post-procedure-pain-bruising/2461549/CoolHealth is entering the U.S. market with TargetCool. Leveraging tuneable cooling technology, TargetCool rapidly cools the skin, allowing providers to specifically set a “target” skin temperature down to the exact degree and
- NRS Announces 2023 Rosacea Awareness Month Theme: Give New Treatments Time to Workhttps://practicaldermatology.com/news/nrs-announces-2023-rosacea-awareness-month-theme-give-new-treatments-enough-time-to-work/2461547/This Rosacea Awareness Month, the National Rosacea Society (NRS) is highlighting the importance of consistency and patience when trying new therapies. “Rosacea has no cure, but the signs and symptoms can go into remission through a combination of medical therapy and life
- MTX Use May Up Risk for Three Types of Skin Cancerhttps://practicaldermatology.com/news/mtx-use-may-up-skin-cancer-risk/2461546/Methotrexate (MTX) may increase risk for three types of skin cancer, according to a new study out of University of Gothenburg. Patients receiving the drug include those with moderate to severe psoriasis; but in this particular patient group, a risk increase was only observed for basal c
- Dermalogica Launches New Course on Treating Melanin-Rich Skinhttps://practicaldermatology.com/news/dermalogica-launches-new-course-on-treating-melanin-rich-skin/2461545/In a move to address under-representation in the professional skin care industry’s training curricula regarding melanin-rich skin tones (specifically those categorized as Fitzpatrick levels IV-VI), Dermalogica announced it is launching “Treating Melanin-Rich Skin.” <
- Avero Diagnostics Launches Test for Early-Stage Melanoma Progressionhttps://practicaldermatology.com/news/avero-diagnostics-launches-test-for-early-stage-melanoma-progression/2461541/Avero Diagnostics announced the US launch of AMBLor, a laboratory test for the identification of early-stage melanomas at low risk of progression. AMBLor technology identifies the presence of two prognostic biomarker proteins, AMBRA1 and loricrin, in the skin overlying the tumor, a
- Evelo Biosciences’ Atopic Dermatitis Candidate Misses Primary Endpoint in Phase 2 Trialhttps://practicaldermatology.com/news/evelo-biosciences-atopic-dermatitis-candidate-misses-primary-endpoint-in-phase-2-trial/2461540/Data from first three cohorts of Evelo Biosciences’ EDP1815 Phase 2 trial show the atopic dermatitis drug candidate did not meet the primary endpoint, the company announced on Wednesday. Evelo stated that there was an unusually high placebo response rate in the first three cohorts of the st
- Game On: Top Derm Video Game Boosts Clinical Decision Making Among Seasoned Doctorshttps://practicaldermatology.com/news/game-on-top-derm-video-game-boosts-clinical-decision-making-among-seasoned-doctors/2461534/Medical video games increase the competence and clinical decision-making of practicing physicians, a new study by Level Ex shows. Substantial research has demonstrated video-game-based medical training’s effectiveness in the short-term. These studies primarily focused on medi
- Study: 3D-printed Artificial Skin Can Be Used in Cosmetics and Drug Testinghttps://practicaldermatology.com/news/study-3d-printed-artificial-skin-can-be-used-in-cosmetics-and-drug-testing/2461525/Bioprinted artificial skin can be used in cosmetics and drug testing, a new study shows. For the study, researchers compared the conventional mimetic model based on manual pipetting with extrusion bioprinting, which “allows the in vitro reconstruction of a more relevant and repres
- Bristol Myers Squibb Receives Positive CHMP Opinion for Once-Daily Sotyktu as Plaque Psoriasis Treatmenthttps://practicaldermatology.com/news/bristol-myers-squibb-receives-positive-chmp-opinion-for-once-daily-sotyktu-as-plaque-psoriasis-treatment/2461522/Four months after receiving FDA approval, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended the approval of Sotyktu (deucravacitinib; Bristol Myers Squibb) for the treatment of adults with moderate-to-severe plaque psoriasis.